Advertisement
DHR or MTD or RVTY
Which Stock Would AI Choose? Danaher Corporation (DHR) vs. Mettler-Toledo International Inc. (MTD) vs. Revvity, Inc. (RVTY) Stock Comparison
Key Takeaways
- Danaher (DHR) leads year-to-date (YTD) performance with approximately 24% gains, significantly outpacing Mettler-Toledo (MTD) and Revvity (RVTY) at around 10% each.
- DHR boasts the largest market capitalization at over $122 billion, reflecting its scale in biotechnology, life sciences, and diagnostics.
- Recent market activity shows DHR advancing toward its Masimo acquisition, boosting sentiment, while MTD and RVTY face upcoming earnings scrutiny.
- Valuation metrics highlight RVTY's elevated trailing price-to-earnings (P/E) ratio of 42, compared to DHR's 34 and MTD's 30.
- Analyst sentiment leans positive for DHR and MTD with overweight ratings, amid sector pressures in life sciences tools.
Introduction
Danaher Corporation (DHR), Mettler-Toledo International Inc. (MTD), and Revvity, Inc. (RVTY) operate in the diagnostics and research segment of healthcare, providing instruments, reagents, and services for life sciences and lab applications. This stock comparison analyzes their recent performance, business drivers, and market positioning amid evolving sector dynamics like biopharma spending and acquisition activity. Traders seeking momentum plays and investors focused on relative valuation in scientific tools will find insights into contrasts in scale, growth trajectories, and risk profiles.
DHR Overview and Recent Performance
Danaher Corporation (DHR) is a global leader in biotechnology, life sciences, and diagnostics, offering instruments, consumables, and services for therapeutics development, cell culture, and clinical testing. In recent weeks, DHR shares have traded near the lower end of their 52-week range (172-243), with a current price around $173 and YTD gains of 24%. Sentiment has been supported by progress on the Masimo acquisition, including shareholder approvals and debt financing, alongside strong earnings quality and free cash flow generation. Market positioning reflects resilience in a pressured sector, with analyst targets averaging $250.
MTD Overview and Recent Performance
Mettler-Toledo International Inc. (MTD) specializes in precision instruments for laboratory, industrial, and retail applications, including balances, pipettes, and analytical tools serving pharma, food, and chemical sectors. Recent market activity has seen MTD shares around $1,258, within a 52-week range of 1,052-1,525, posting YTD returns of about 10%. Performance reflects mixed signals with stagnant revenue growth noted ahead of Q1 earnings, though profitability remains robust. Analyst consensus points to a $1,488 target, amid challenges in returns on capital.
RVTY Overview and Recent Performance
Revvity, Inc. (RVTY) delivers health sciences solutions, including detection technologies, reagents, and software for genomics, diagnostics, and drug discovery. Shares have hovered near $87 in recent weeks, in a 52-week range of 81-118, with YTD performance around 10%. Recent developments include shareholder re-election of the board, but sentiment is tempered by weak revenue growth and margin pressures ahead of earnings. The stock's trajectory underscores sector headwinds in life sciences tools.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases 25 top-performing AI trading bots curated from over 350 available bots that trade thousands of tickers across stocks, ETFs, and crypto. These bots employ diverse strategies like trend trading, multi-agent systems with take-profit/stop-loss corridors (e.g., 3% TP/2% SL), and AI/ML signals on timeframes from 5 minutes to 60 minutes. Highlighted stats include annualized returns ranging from 23% to 162%, win rates of 51% to 88%, profit factors up to 11.7, and profit-to-drawdown ratios as high as 17. Only the most suitable for current conditions earn a spot here, offering varied styles for short-term scalping to longer holds. Explore these bots to align with your trading approach in dynamic markets.
Head-to-Head Comparison
DHR, MTD, and RVTY share exposure to diagnostics and research tools but differ in business models: DHR's diversified segments drive scale advantages, while MTD emphasizes precision hardware across industries, and RVTY focuses on genomic workflows. Growth drivers favor DHR with acquisition catalysts versus peers' organic challenges. Recent momentum tilts to DHR's YTD outperformance. Risk profiles show DHR lowest beta (0.84), RVTY at 1.05, and MTD highest (1.31). Valuation sensitivity is evident in RVTY's premium trailing P/E amid forward compression; market sentiment aligns with analysts' preference for larger peers.
Tickeron AI Verdict
Tickeron’s AI models would likely favor DHR in the current environment, given its superior trend consistency, YTD momentum, acquisition catalysts, and relative stability versus peers' earnings uncertainties and weaker growth signals. Probabilistic edges point to stronger positioning amid life sciences sector volatility, though all carry biopharma exposure risks.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
DHR’s FA Score shows that 1 FA rating(s) are green whileMTD’s FA Score has 1 green FA rating(s), and RVTY’s FA Score reflects 1 green FA rating(s).
- DHR’s FA Score: 1 green, 4 red.
- MTD’s FA Score: 1 green, 4 red.
- RVTY’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
DHR’s TA Score shows that 4 TA indicator(s) are bullish while MTD’s TA Score has 4 bullish TA indicator(s), and RVTY’s TA Score reflects 6 bullish TA indicator(s).
- DHR’s TA Score: 4 bullish, 4 bearish.
- MTD’s TA Score: 4 bullish, 6 bearish.
- RVTY’s TA Score: 6 bullish, 5 bearish.
Price Growth
DHR (@Medical Specialties) experienced а -4.79% price change this week, while MTD (@Medical Specialties) price change was -17.66% , and RVTY (@Medical Specialties) price fluctuated +7.58% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -0.13%. For the same industry, the average monthly price growth was +1.59%, and the average quarterly price growth was -8.22%.
Reported Earning Dates
DHR is expected to report earnings on Jul 28, 2026.
MTD is expected to report earnings on Jul 23, 2026.
RVTY is expected to report earnings on Aug 03, 2026.
Industries' Descriptions
@Medical Specialties (-0.13% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| DHR | MTD | RVTY | |
| Capitalization | 118B | 21.7B | 11.1B |
| EBITDA | 7.08B | 1.24B | 766M |
| Gain YTD | -27.217 | -23.077 | 2.778 |
| P/E Ratio | 32.22 | 25.19 | 47.84 |
| Revenue | 24.8B | 4.03B | 2.86B |
| Total Cash | 5.7B | 66.9M | N/A |
| Total Debt | 18.5B | 2.15B | 3.4B |
DHR | MTD | RVTY | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 55 | 51 | 70 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 20 Undervalued | 99 Overvalued | 52 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | 100 | |
SMR RATING 1..100 | 78 | 3 | 88 | |
PRICE GROWTH RATING 1..100 | 64 | 64 | 48 | |
P/E GROWTH RATING 1..100 | 69 | 66 | 32 | |
SEASONALITY SCORE 1..100 | 45 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
DHR's Valuation (20) in the Medical Specialties industry is in the same range as RVTY (52) and is significantly better than the same rating for MTD (99). This means that DHR's stock grew similarly to RVTY’s and significantly faster than MTD’s over the last 12 months.
DHR's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as RVTY (100) and is in the same range as MTD (100). This means that DHR's stock grew similarly to RVTY’s and similarly to MTD’s over the last 12 months.
MTD's SMR Rating (3) in the Medical Specialties industry is significantly better than the same rating for DHR (78) and is significantly better than the same rating for RVTY (88). This means that MTD's stock grew significantly faster than DHR’s and significantly faster than RVTY’s over the last 12 months.
RVTY's Price Growth Rating (48) in the Medical Specialties industry is in the same range as MTD (64) and is in the same range as DHR (64). This means that RVTY's stock grew similarly to MTD’s and similarly to DHR’s over the last 12 months.
RVTY's P/E Growth Rating (32) in the Medical Specialties industry is somewhat better than the same rating for MTD (66) and is somewhat better than the same rating for DHR (69). This means that RVTY's stock grew somewhat faster than MTD’s and somewhat faster than DHR’s over the last 12 months.
| DHR | MTD | RVTY | |
|---|---|---|---|
| RSI ODDS (%) | 1 day ago 58% | 2 days ago 67% | 2 days ago 75% |
| Stochastic ODDS (%) | 1 day ago 59% | 2 days ago 55% | 2 days ago 76% |
| Momentum ODDS (%) | 1 day ago 67% | 2 days ago 60% | 2 days ago 70% |
| MACD ODDS (%) | 1 day ago 65% | 2 days ago 69% | 2 days ago 72% |
| TrendWeek ODDS (%) | 1 day ago 63% | 2 days ago 63% | 2 days ago 65% |
| TrendMonth ODDS (%) | 1 day ago 66% | 2 days ago 66% | 2 days ago 61% |
| Advances ODDS (%) | 6 days ago 54% | 7 days ago 63% | 7 days ago 66% |
| Declines ODDS (%) | 1 day ago 60% | 2 days ago 63% | 14 days ago 66% |
| BollingerBands ODDS (%) | 1 day ago 57% | 2 days ago 74% | 2 days ago 77% |
| Aroon ODDS (%) | 5 days ago 55% | 2 days ago 63% | 2 days ago 61% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| KJUN | 29.14 | 0.01 | +0.05% |
| Innovator U.S. Small Cp Pwr Buf ETF -Jun | |||
| SDCP | 25.65 | N/A | N/A |
| Virtus Newfleet Short Dur Cor Pls Bd ETF | |||
| IGSB | 52.38 | -0.05 | -0.09% |
| iShares 1-5 Year invmt Grd Corp Bd ETF | |||
| SIHY | 45.24 | -0.09 | -0.20% |
| Harbor Ares Systematic High-Yield ETF | |||
| ASGI | 23.91 | -0.10 | -0.42% |
| abrdn Global Infrastructure Income Fund | |||
MTD and
Correlation & Price change
A.I.dvisor indicates that over the last year, MTD has been closely correlated with A. These tickers have moved in lockstep 76% of the time. This A.I.-generated data suggests there is a high statistical probability that if MTD jumps, then A could also see price increases.
| Ticker / NAME | Correlation To MTD | 1D Price Change % | ||
|---|---|---|---|---|
| MTD | 100% | -0.56% | ||
| A - MTD | 76% Closely correlated | +1.29% | ||
| RVTY - MTD | 73% Closely correlated | +0.35% | ||
| TMO - MTD | 70% Closely correlated | +1.48% | ||
| DHR - MTD | 68% Closely correlated | -0.16% | ||
| BRKR - MTD | 67% Closely correlated | +3.37% | ||
More | ||||
RVTY and
Correlation & Price change
A.I.dvisor indicates that over the last year, RVTY has been closely correlated with A. These tickers have moved in lockstep 73% of the time. This A.I.-generated data suggests there is a high statistical probability that if RVTY jumps, then A could also see price increases.
| Ticker / NAME | Correlation To RVTY | 1D Price Change % | ||
|---|---|---|---|---|
| RVTY | 100% | +0.35% | ||
| A - RVTY | 73% Closely correlated | +1.29% | ||
| TMO - RVTY | 73% Closely correlated | +1.48% | ||
| IQV - RVTY | 69% Closely correlated | +0.87% | ||
| DHR - RVTY | 68% Closely correlated | -0.16% | ||
| CRL - RVTY | 66% Loosely correlated | +0.14% | ||
More | ||||